The
The venture will allow them to see the potentially market-moving postings for a price.
Some doctors told The Wall Street Journal, however, they are skeptical that the service will actually affect medical advancements, and a pharmaceutical group noted that it could become a rumor mill.
But the AMA is looking forward to the ability to survey its members, just as Sermo’s 10 to 20 existing Wall Street subscribers appreciate the insight into the medical community. Sermo executives said they will continue to keep the service, which is being funded with $11.5 million in venture capital, impartial by excluding drug or medical device companies from signing up. While the service is free to doctors who share personal information, non-medical subscribers pay between $100,000 to $500,000 a year.